Bactrim is a combination of sulfamethoxazole and trimethoprim. Its clinically important interactions involve more than one pathway: effects on drug metabolism, renal transport, bleeding risk, potassium balance and blood-cell production. A reliable interaction check must include prescriptions, over-the-counter medicines and supplements as well as the patient’s kidney function, age and existing illnesses.
The U.S. Bactrim label highlights combinations such as warfarin, methotrexate, selected blood-pressure medicines, phenytoin and dofetilide. Dofetilide use together with Bactrim is contraindicated because of potentially serious heart-rhythm effects. Other combinations may require avoidance, an alternative antibiotic or specific monitoring. A complete medication review cannot be replaced by a short internet list.
This page organizes interaction categories to prepare for pharmacist screening. For anticoagulation details use the focused warfarin and INR page; for another high-risk combination, see the methotrexate toxicity guide.
Trimethoprim and sulfamethoxazole affect different transporters and metabolic pathways. The practical significance depends on which other drugs a patient takes, their exposure and existing medical risk. Even common chronic medicines can become relevant to a short antibiotic prescription, so medication reconciliation should happen before dispensing.
Bactrim can prolong prothrombin time in patients taking warfarin. The product label calls for monitoring prothrombin time and INR, with clinical oversight of any adjustment. Patients should not independently stop anticoagulation or make schedule changes based on a drug-interaction website.
The Bactrim label advises avoiding concurrent use with methotrexate. Interactions involving renal handling and protein binding can raise methotrexate exposure; overlapping adverse effects may include bone-marrow suppression. The prescriber must review the exact medication list before selecting an antibiotic.
Trimethoprim can increase serum potassium. Patients taking an ACE inhibitor, certain other blood-pressure agents or potassium-sparing medicines may have additive risk, particularly with impaired kidney function. A clinician may choose a different medicine or arrange potassium and renal testing depending on the scenario.
The table prioritizes drug combinations by the kind of clinical action they may require. Dofetilide is a contraindicated combination under Bactrim labeling, which is materially different from interactions that call for monitoring or a change of treatment. A prescriber or pharmacist must interpret the full medication list and renal status; patients should not stop maintenance medicines or adjust doses on the basis of this summary.
| Drug or class | Interaction concern | Typical clinical approach |
|---|---|---|
| Warfarin | Excess anticoagulant effect | INR assessment and oversight |
| Methotrexate | Increased exposure/toxicity | Avoid concurrent use per label |
| Dofetilide | Potential dangerous arrhythmia | Contraindicated combination |
| ACE inhibitors | Potential high potassium | Clinician risk review and laboratory follow-up |
| Phenytoin | Reduced clearance | Monitoring for toxicity |
| Digoxin | Elevated concentrations | Selected patients need level review |
Concomitant administration of Bactrim and dofetilide is contraindicated in the official label. That is more restrictive than a general suggestion to “monitor.” Other drugs, including procainamide, have separate interaction guidance. Always supply a complete cardiac-medication list rather than relying on a partial online profile.
Phenytoin, digoxin, certain oral glucose-lowering medicines, cyclosporine, diuretics and zidovudine appear in labeling interaction discussions. Their risk-management recommendations differ. Inform the pharmacist of doses and current usage, and ask whether a contraindication, monitoring or alternative prescription applies.
Medication lists change between appointments. A patient may have started a new anticoagulant or blood-pressure treatment, received a temporary pain medicine, or stopped a drug without updating every clinician. The interaction question therefore has to be answered for the medicines being taken today, not the list available when Bactrim was last prescribed. Pharmacies can identify potential conflicts, but some decisions require access to laboratory values and the reason for the antibiotic. When the information is incomplete, contacting the prescriber is safer than silently proceeding.
Bring an updated list showing exact names, strengths and when each medication is taken, including intermittent prescriptions. Do not assume a drug was reviewed just because it has been prescribed for years. The potassium-focused page explains one specific interaction mechanism in greater detail.
Yes. Warfarin is a notable interaction and may require closer INR assessment.
The prescribing label advises avoiding concurrent use; the prescriber should select the plan.
No. Bactrim labeling lists coadministration as contraindicated.
Yes. Some drug combinations and kidney conditions increase the risk.
No. It highlights important label-identified categories, not a complete medication database.
No. Ask the treating clinician how to manage the combination.
They should be included in medication reconciliation because they may affect the overall assessment.